Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Hodgkin Disease 2Burkitt Lymphoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Teratoma 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia 1Heart Failure 1Glioma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Dendritic Cell Sarcoma, Interdigitating 1Choriocarcinoma 1Central Nervous System Neoplasms 1Cardiotoxicity 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5pembrolizumab 4Cyclophosphamide 4olaparib 3liposomal doxorubicin 3fludarabine 3ribociclib 2palbociclib 2mirvetuximab soravtansine 2Topotecan 2Nivolumab 2Letrozole 2Fulvestrant 2Blood Specimen Collection 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1niraparib 1lenvatinib 1isoquercitrin 1fludarabine phosphate 1durvalumab 1cemiplimab 1abemaciclib 1Tinzaparin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1SLC25A33 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Ovarian Epithelial × pegfilgrastim × Clear all
NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

TORL Biotherapeutics, LLC

Phase 2 Recruiting
230 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡